# **Data Changes for the CCDD JUNE Release Candidate 2024**

## **Based on the QA Release Generation** 2024-06-03

|  |  |
| --- | --- |
| Data entered by | A.Raghuveer |
| Data checked by | J.Hutsul |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] |  |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8002443 | famtozinameran and tozinameran |
| 8002394 | sotrovimab |

## **NTP File**

### **Deprecation**

The following NTP concept(s) needs to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  |  |

### **Status update – Inactive**

The following NTP concept(s) are generating as Active but need to be set to **inactive** to align with their respective MPs.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Inactive |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9014778 | famtozinameran 15 mcg per 0.3 mL and tozinameran 15 mcg per 0.3 mL suspension for injection 1.8 mL vial |
| 9014820 | famtozinameran 5 mcg per 0.2 mL and tozinameran 5 mcg per 0.2 mL suspension for injection 2 mL vial |
| 9014631 | sotrovimab 500 mg per 8 mL solution for injection vial |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. The product has been transferred from DPD to LNHPD.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – deprecation**

The following MP concepts are generating as active but need to be set to **deprecated**. Some of these products have been assigned a new DIN, others have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Deprec |

### **Status update – Inactive**

The following MP concepts are generating as active but need to be set to **inactivated**. The DIN is still active but these particular presentations have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Inactive |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Code permanence – name changes**

The following MP concept(s) need to keep its/their existing mp\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **mp\_code (to keep)** | **mp \_formal\_name** | **mp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Inclusion list to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 6547 | 497193 | AMINOPHYLLINE INJECTION USP (aminophylline 250 mg per 10 mL solution for injection vial) PFIZER CANADA ULC | Dormant 2024.05.09 |
| 15903 | 1916858 | CLAVULIN 500 F TAB (amoxicillin (amoxicillin trihydrate) 500 mg and clavulanic acid (potassium clavulanate) 125 mg oral tablet) GLAXOSMITHKLINE INC | Canceled post-market 2024-05-26 |
| 102060 | 2531461 | COMIRNATY ORIGINAL & OMICRON BA.4/BA.5 (famtozinameran 15 mcg per 0.3 mL and tozinameran 15 mcg per 0.3 mL suspension for injection 1.8 mL vial) BIONTECH MANUFACTURING GMBH | Canceled post-market 2024-05-03 |
| 102220 | 2533197 | COMIRNATY ORIGINAL & OMICRON BA.4/BA.5 (famtozinameran 5 mcg per 0.2 mL and tozinameran 5 mcg per 0.2 mL suspension for injection 2 mL vial) BIONTECH MANUFACTURING GMBH | Canceled post-market 2024-05-03 |
| 77628 | 2290863 | DAYTIME COLD/FLU MEDICINE (acetaminophen 650 mg per 30 mL and dextromethorphan hydrobromide 20 mg per 30 mL and phenylephrine hydrochloride 10 mg per 30 mL oral solution) PERRIGO INTERNATIONAL | Canceled post-market 2024-05-31 |
| 64096 | 2240526 | DENTICARE CHLORHEXIDINE GLUCONATE ORAL RINSE 0.12% (chlorhexidine gluconate 0.12 % mouthwash) AMD MEDICOM INC | Canceled post-market 2024-05-31 |
| 12221 | 1926853 | FLAGYL (metronidazole 500 mg oral capsule) SANOFI-AVENTIS CANADA INC | Canceled pre-market 2024-05-15 |
| 96049 | 2471388 | M-CLARITHROMYCIN (clarithromycin 250 mg oral tablet) MANTRA PHARMA INC | Canceled post-market 2024-05-31 |
| 96720 | 2476185 | MAR-FLECAINIDE (flecainide acetate 100 mg oral tablet) MARCAN PHARMACEUTICALS INC | Dormant 2024.01.17 |
| 96719 | 2476177 | MAR-FLECAINIDE (flecainide acetate 50 mg oral tablet) MARCAN PHARMACEUTICALS INC | Dormant 2023.10.24 |
| 67506 | 2243588 | MYLAN-NITRO SUBLINGUAL SPRAY (nitroglycerin 0.4 mg per actuation sublingual spray) MYLAN PHARMACEUTICALS ULC | Canceled post-market 2023.07.31 |
| 86446 | 2378655 | NIGHTTIME COLD AND FLU RELIEF (acetaminophen 650 mg per 30 mL and dextromethorphan hydrobromide 30 mg per 30 mL and doxylamine succinate 12.5 mg per 30 mL oral solution) PERRIGO INTERNATIONAL | Canceled post-market 2024-05-31 |
| 93086 | 2445573 | OPTI-TEARS ALLERGY (naphazoline hydrochloride 0.025 % and pheniramine maleate 0.3 % ophthalmic drops) ALCON CANADA INC | Canceled post-market 2024-05-31 |
| 80950 | 2324024 | PREZISTA (darunavir (darunavir ethanolate) 600 mg oral tablet) JANSSEN INC | Canceled post-market 2024-05-31 |
| 100768 | 2518341 | SOTROVIMAB FOR INJECTION (sotrovimab 500 mg per 8 mL solution for injection vial) GLAXOSMITHKLINE INC | AUTHORIZATION (INTERIM ORDER) REVOKED 2024-04-29 |
| 91135 | 2426781 | TEVA-VARENICLINE (varenicline (varenicline tartrate) 0.5 mg oral tablet with varenicline (varenicline tartrate) 1 mg oral tablet) TEVA CANADA LIMITED | Dormant 2024.05.03 |
| 91083 | 2426226 | TEVA-VARENICLINE (varenicline (varenicline tartrate) 0.5 mg oral tablet) TEVA CANADA LIMITED | Dormant 2024.05.03 |
| 91084 | 2426234 | TEVA-VARENICLINE (varenicline (varenicline tartrate) 1 mg oral tablet) TEVA CANADA LIMITED | Dormant 2024.05.03 |
| 82322 | 2337649 | TOCTINO (alitretinoin 30 mg oral capsule) GLAXOSMITHKLINE INC | Canceled post-market 2024-05-31 |

## **Exclusion List (on GitHub)**

The following changes have been made to the Exclusion List for the MAY 2024 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Exclusion List are as follows:  
ACTION is either:

* STAY on Exclusion List
* ADD to Exclusion List
* REMOVE from Exclusion List

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 02515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |
| 7606e1a96d2ac94e7ff92db13645c067 | eptifibatide 75 mg per 100 mL solution for injection vial | 102949 | 02540819 | EPTIFIBATIDE INJECTION (eptifibatide 75 mg per 100 mL solution for injection vial) JUNO PHARMACEUTICALS CORP. | ADD |
| a30d007d8eb894ed1b8e493a5447e04b | irinotecan hydrochloride 20 mg per mL solution for injection | 93881 | 02452421 | IRINOTECAN HYDROCHLORIDE INJECTION, USP (irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20 mg per mL solution for injection) GENERIC MEDICAL PARTNERS INC | ADD |
| eeb594428066966a2e013d25880ac0f7 | lacosamide 10 mg per mL solution for injection | 102997 | 02541343 | LACOSAMIDE INJECTION, USP (lacosamide 10 mg per mL solution for injection) HIKMA CANADA LIMITED | ADD |